Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma

Journal of Immunotherapy

Volumn 27, Issue 5, 2004, Pages 398-404

  Dillman, Robert O ^a   Duma, Christopher M ^a   Schiltz, Patric M ^a   DePriest, Carol ^a   Ellis, Robin A ^a   Okamoto, Kris ^a   Beutel, Linda D ^a   De Leon, Cristina ^a   Chico, Sherri ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

Author keywords

Adoptive cell therapy; Glioblastoma; Immunotherapy; Lymphokine activated killer cells

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; LEUKAPHERESIS; LYMPHOKINE ACTIVATED KILLER CELL; PATIENT MONITORING; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 4344689067     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200409000-00009     Document Type: Article

References (32)

1. Jema A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
2. Bruner JM. Neuropathology of malignant gliomas. Semin Oncol. 1994; 21:126-138.
3. Legler JM, Gloeckler Reis LA, Smith MA, et al. Brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst. 1999;91:1382-1390.
4. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114-123.
5. Croteau D, Mikkelsen T. Adults with newly diagnosed high-grade gliomas. Curr Treat Options Oncol. 2001;2:507-515.
6. Nwokedi EC, DiBiase SJ, Jabbour S, et al. Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme. Neurosurgery. 2002;50:41-46.
7. Seiferheld WF, Mehta MP, Del Rowe J, et al. Five years of glioblastoma multiforme (GBM) phase II trials at the radiation therapy oncology group (RTOG) [abstract]. Proc Am Soc Oncol. 2002;21:71a.
8. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000;6:2585-2597.
9. Fin HA, Dear KB, Loeffler J. S, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993;71:2582-2597.
10. Dillman RO. American College of Surgeons Annual Report 2002: Central Nervous System Tumors [monograph]. January 2003.
11. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 either alone or in combination with lymphokine activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993;85:623-632.
12. Dillman RO, Oldham RK, Tauer KW, et al. Continuous interleukin-2 and lymphokine activated killer cells for advanced cancer: a National Biotherapy Study Group trial. J Clin Oncol. 1991;7:1233-1240.
13. Jacobs SK, Wilson DJ, Komblith PL, et al. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res. 1986;46:2102-2104.
14. Yoshida S, Tanaka R, Takai N, et al. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with malignant brain tumors. Cancer Res. 1988;48:5011-5016.
15. Merchant RE, Grant AJ, Merchant LH, et al. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer. 1988;62:665-671.
16. Barba D, Saris SC, Holder C, et al. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg. 1989;70:175-182.
17. Ingram M, Buckwalter JG, Jacques DB, et al. Immunotherapy for recurrent malignant glioma: an interim report on survival. Neurol Res. 1990; 12:265-273.
18. Lillehei KO, Mitchell DH, Johnson SD, et al. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery. 1991;28:16-23.
19. Jeffes EW 3rd, Beamer YB, Jacques S, et al. Therapy of recurrent high-grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA. J Neurooncol. 1993;15:141-155.
20. Hayes RL, Koslow M, Hiesiger EM, et al. Improved long-term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer. 1995;76:840-852.
21. Schiltz PM, Beutel LD, Nayak SK, et al. Characterization of tumor infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer. J Immunother. 1997;20:377-386.
22. Malone CC, Schiltz PM, Mackintosh AD, et al. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer. Cancer Biotherapy Radiopharm. 2001;16: 381-390.
23. Kruse CA, Mitchell DH, Lillehei KO, et al. Interleukin-2-activated lymphocytes from brain tumor patients: a comparison of two preparations generated in vitro. Cancer. 1989;64:1629-1637.
24. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572-2578.
25. Salcman M, Scholtz H, Kaplan RS, et al. Long-term survival in patients with malignant astrocytoma. Neurosurgery. 1994;34:213-217.
26. Brandes AA, Vastola F, Monfardini S. Reoperation in recurrent high-grade gliomas. Am J Clin Oncol. 1999;22:387-390.
27. Ammirati M, Galicich JH, Arbit E, et al. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery. 1987;21:607-614.
28. Harsh GR 4th, Levin VA, Gutin PH, et al. Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery. 1987;21:615-621.
29. Sipos L, Afra D. Re-operations of supratentorial anaplastic astrocytomas. Acta Neurochir. 1997;139:99-104.
30. Dirks P, Bernstein M, Muller PJ, et al. The value of reoperation for recurrent glioblastoma. Can J Surg. 1993;36:271-275.
31. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995;345:1008-1012.
32. Gliadel wafers for treatment of brain tumors. Med Lett Drugs Ther. 1998; 40:92.